Marion McCourt - Jun 3, 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Commercial
Signature
/s/**Marion McCourt
Stock symbol
REGN
Transactions as of
Jun 3, 2024
Transactions value $
-$691,563
Form type
4
Date filed
6/5/2024, 04:07 PM
Previous filing
May 3, 2024
Next filing
Jul 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $424 K +1.14 K +8.8% $372.46 14.1 K Jun 3, 2024 Direct F1
transaction REGN Common Stock Sale -$1.12 M -1.14 K -8.09% $980.16 12.9 K Jun 3, 2024 Direct F1
holding REGN Common Stock 174 Jun 3, 2024 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -1.14 K -33.35% $0.00 2.27 K Jun 3, 2024 Common Stock 1.14 K $372.46 Direct F1, F2

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c) adopted on February 13, 2024.
F2 The stock option award vests in four equal annual installments, commencing one year after the date of grant.